Colleen Silk: Fueling Innovation in Rare Bleeding Disorders at THSNA 2026
Colleen Silk, Corporate Vice President, Rare Disease at Novo Nordisk, shared on LinkedIn:
”This weekend I attended the 2026 Thrombosis and Hemostasis Summit of North America alongside many dedicated colleagues from our Rare Disease team.
I left feeling inspired by the collaboration and expertise that went into making this meeting such a valuable experience.
It was energizing to connect with the thrombosis and hemostasis community, sharing scientific perspectives and how we’re working to shape the future of care for people living with hemophilia.
From scientific presentations to educational symposia, our presence reflected a continued focus on innovation and progress for the rare bleeding disorders community.
THSNA reinforced the power of fueling conversations, sharing insights, and learning together matters as we work to accelerate progress in this area of unmet need.”
Stay updated with Hemostasis Today.
-
Apr 14, 2026, 13:09Yan Leyfman: Rewriting Sickle Cell Disease Biology with CRISPR Technology
-
Apr 14, 2026, 13:01Shahzaib Maqbool: Preeclampsia Through a Hematology Lens
-
Apr 14, 2026, 12:46Rosa Hart: Inside Pediatric Stroke Recovery with Dr. Catherine Schuster
-
Apr 14, 2026, 12:39Gonzalo Ladreda: Innovation in Stroke Care Is About Timing, Integration, and Real-World Usability
-
Apr 14, 2026, 12:30Roy P.C. Kessels: Stroke’s Cognitive Impact on Young Adults Is Significant and Often Overlooked
-
Apr 14, 2026, 12:22Mehari Gebreyohanns: New Insights on Wake-Up Strokes from Emergency Settings in Texas and Louisiana
-
Apr 14, 2026, 12:08Enrico Ferro: Comparative Study Raises Questions on PFA Safety in AF at EHRA 2026
-
Apr 14, 2026, 11:39Prachi Patel: How B Vitamins and Large-Scale Research Are Shaping Stroke Prevention
-
Apr 14, 2026, 11:28Jamie Brannigan: Help Shape the Future of Brain-Computer Interfaces in Stroke and Neurological Care